ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sofinnova Partners, a Paris-based life sciences venture capital firm, has established a business to translate intellectual property into biotech start-ups in Italy. Sofinnova claims its new business, named BiovelocITA, is the first of its kind in the country. Sofinnova and a group of private investors have seeded BiovelocITA with more than $6 million. BiovelocITA is evaluating more than 10 projects including some from TTFactor, an organization representing major Italian research institutes. “There is a window of opportunity in Italy: The science is excellent, and the pool of entrepreneurs is growing,” says Graziano Seghezzi, a Sofinnova partner.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter